Mayor hopes letter to Health Canada will breathe life back into Vida Cannabis's plan to open plant.

The Town of Stellarton, N.S., is urging Health Canada to quickly approve a proposed medical marijuana production facility in the community, an enterprise the mayor says would bring much-needed jobs to the area.

At a town council meeting this week, a motion was passed to write a letter to Health Canada in support of Vida Cannabis's plan to operate a pot plant at the old Clairtone building on Acadia Street.

"The intent of it was to expedite the process of making 114 Acadia St. as operations for a cannabis production facility," said Stellarton Mayor Danny MacGillivray.

With just one word — Erbachay — is raising a lot of eyebrows around Saskatchewan.

The ads, displayed in Regina and Saskatoon, show a green leaf with the word “Erbachay” and “Canada Wide Delivery.”

The company behind the signs are a Vancouver-based medical marijuana dispensary that sells and delivers weed.

“By putting these billboards up, we’re trying to help that process. Make it a little more normalized, make it more accessible,” Erbachay Health Centers president Darcy Delainey said.

Erbachay isn’t a licensed producer for cannabis with Health Canada but within Vancouver city limits, Delainey said he can sell medical marijuana.

The billboards are a way to educate the public and hopefully destigmatize weed, he said.

The Utah Medical Association not only wants to stop marijuana from becoming legal for medical use in Utah, it wants reporters to stop using the term "medical marijuana."

But Cristine Steinquist has a brain tumor and says marijuana helps.

"It helps the nausea and the pain," she said.

But according to doctors, anecdotal stories do not make something medical. 

The increasing supply of legal marijuana is turning into a major buzz kill for growers as prices plunge — and an opportunity for companies that can help cut production costs.

Prices are tumbling as formerly illicit cultivators emerge from the shadows to invest millions of dollars in massive pot factories. In Colorado, the average price sought by wholesalers has fallen 48 per cent to about US$1,300 a pound since legal sales to all adults started in January 2014, according to Cannabase, operator of the state’s largest market. Supply is surging as growers expand and install the latest agricultural technology.

An estimated 400,000 Americans are currently living with multiple sclerosis, an autoimmune disease where the body’s immune cells attack a fatty substance called myelin in the nerves. Common symptoms are gait and balance disorders, cognitive dysfunction, fatigue, pain and muscle spasticity.

Colorado has the highest proportion of people living with MS in the United States. It is estimated that one in 550 people living in the state has MS, compared to one in 750 nationally. The reason for this is unknown, but could be related to several factors, such as vitamin D deficiency or environment.

Concentrates can refer to a multitude of products in the world of cannabis – from oil to wax to shatter. The term is a generic way to reference any cannabis product that has been created through the extraction of cannabinoids from the plant.

Concentrates are growing in popularity and are generally considered some of the most refined cannabis products. Although a few forms of concentrates have been used all over the world for hundreds of years, many are recent innovations created to meet the demands of a newly-legalized mass market.

Medicinal cannabis company Creso Pharma, which aims to launch two medicinal cannabis pet products by April, has been registered by the EU health authority.

An Australian pharmaceutical developer has received the European Union's first ever health registration to commercialise medical cannabis for pets.

ASX-listed Creso Pharma is now registered with the EU and is in the process of applying for a global import and export license as it aims to sell two cannabidiol-based pet products by April.

The products, which are essentially food additives for horses and dogs, are designed to help target behavioural disorders including anxiety and noise phobias as well as chronic pain, arthritis and diabetes.

With a new year and a new presidential administration set to begin, my firm is fielding a lot of questions about what is going to happen and is hearing a lot of claims about the cannabis industry that just aren’t true. In the past, I’ve written about the top 10 industry red flags and the top 10 industry red herrings. In this post, I discuss the following six bogus claims about the marijuana industry:

President-elect Donald Trump and appointee U.S. Attorney General Jeff Sessions will not impair state-legal marijuana.

The Arkansas House voted Tuesday to delay the launch of the state’s voter-approved medical marijuana program and ease a restriction on doctors who certify a patient is eligible to use the drug.

The bills are among the first of several that lawmakers are expected to take up in the coming weeks as they implement the constitutional amendment that legalizes cannabis for Arkansas residents with certain medical conditions.

The delay proposal, approved on a 91-0 vote, would give state agencies until early May rather than March to finalize the rules. It will also move the state’s deadline to begin accepting applications for dispensaries and cultivation facilities to July 1, rather than June 1.

Test your pot knowledge before you invest in cannabis.

Marijuana legalization has made the marijuana industry incredibly alluring to investors. The marijuana market is expected to surge to $21 billion by 2020, and that's got many people wondering which marijuana stocks could benefit most.

While the marijuana market is undeniably growing quickly, and that's good news for marijuana stocks, most investors don't have enough information about the pros and cons associated with marijuana companies to make the best money-making decisions. Do you have the knowledge necessary to profit from marijuana's explosive growth opportunity?